Navigation Links
MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
Date:5/3/2011

fiscal 2011 full year operating expenses, excluding non-cash charges such as stock-based compensation and depreciation, to be approximately $50 to $55 million. In addition, the Company currently anticipates capital expenditures in 2011 to be approximately $4 to $5 million. As previously disclosed, the Company anticipates loan payments of approximately $8 million in 2011 related to a working capital loan. Collaboration revenues are estimated to be approximately $65 million in 2011. This estimate includes amortization of the upfront payment received in February 2011 and a milestone payment that the Company would be eligible to receive in 2011 under its collaboration agreement with Allergan, if a certain milestone is met.

About MAP PharmaceuticalsMAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX, an orally inhaled investigational drug for the acute treatment of migraine. The Company has reported positive results from its Phase 3 trial of LEVADEX and has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. MAP Pharmaceuticals also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking StatementsIn addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate and MAP Pharmaceuticals' expected cash requirements during 2011 describe
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... --  BioTE Medical , a leading provider of ... today announced the addition of Dr. Neal ... is joining the BioTE Medical Advisory Board as ... was residency trained in Family Medicine and Emergency ... emergency physician still practicing at a large metropolitan ...
(Date:7/22/2014)... The DNA Spectrum Ancestry Map provides ... history, migration, and culture. , Throughout his childhood ... stories stemming from Europe. His father passionately referred to ... 8mm home movies painted an elaborate picture of an ... ordered a test from DNA Spectrum to expand upon ...
(Date:7/22/2014)... SHENZHEN , Cina, 22 luglio 2014 /PRNewswire/ ... filiale di BGI, la maggiore organizzazione di genomica del ... servizio di sequenziamento dell,intero esoma umano con base la ... Complete Genomics, molto apprezzata nel settore per essere ... il 99.999% di precisione e una rilevazione altamente sensibile ...
(Date:7/22/2014)... 22, 2014  Semler Scientific, Inc. (Nasdaq: ... assessment company that develops patented products that assist ... diseases, today announced that it will report second ... U.S. financial markets on July 25, 2014. Doug Murphy-Chutorian, M.D., ... conference call at 11 a.m. EDT, July 25, 2014. ...
Breaking Biology Technology:Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014 2
... BEDMINSTER, N.J., Nov. 8, 2010 Omthera ... company, today announced the initiation of a ... evaluate the bioavailability of Epanova™, Omthera,s lead ... triglycerides, in comparison to Lovaza®, the leading ...
... (Nasdaq: TPCG ) today announced that it has commenced ... of its common stock at a purchase price of not less ... purchase shares having an aggregate purchase price of no more than ... stockholders may tender all or a portion of their shares (1) ...
... at the Kavli Institute of NanoScience, has been awarded ... his research into improved microscopic technologies. The technologies enable ... semiconductor nanowires, all the way down to atomic level. ... are made visible in this way can be measured ...
Cached Biology Technology:Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 2Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 3TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock 2TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock 3TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock 4ERC advanced grant for Professor Zandbergen's 'nanolaboratory' 2
(Date:7/22/2014)... Arlington computer science and engineering professor with an expertise ... National Science Foundation grant worth more than $600,000 to ... fruit fly., Heng Huang, an associate professor, will lead ... UT Arlington Computer Science and Engineering department. Scientists are ... a large number of genes involved in fruit fly ...
(Date:7/22/2014)... the average steak, but it seems to help wood ... winter cold. , "Alaska wood frogs spend more time ... your freezer and the frog comes back to life ... said Don Larson, University of Alaska Fairbanks graduate student ... freeze tolerance in Alaska wood frogs is more extreme ...
(Date:7/22/2014)... the USC Schaeffer Center for Health Policy and ... drugs with increased incarceration rates for schizophrenic individuals. ... whether cutbacks in mental health actually save money, ... Some health plans require an extra approval step ... patients. This step called prior authorization ...
Breaking Biology News(10 mins):UT Arlington big data team wins $600,000 NSF grant to build gene expression database 2Alaska frogs reach record lows in extreme temperature survival 2Alaska frogs reach record lows in extreme temperature survival 3Are state Medicaid policies sentencing people with mental illnesses to prison? 2
... Sept. 26 2007 -- Consuming large amounts of caffeine ... painkillers in the United States, could potentially cause liver ... the Oct. 15 print issue of ACS Chemical Research ... occur not only from drinking caffeinated beverages while taking ...
... the magnetic reference direction, have recently been found in ... 2004). Furthermore, studies investigating what parts of a migratory ... magnetic compass showed that the cryptochrome-containing neurons in the ... al., PNAS, 2005; Liedvogel et al., EJN, 2007) are ...
... 25, 2007) Your body goes to a lot of ... brains neural pathways are impaired through injury, age or illness, ... to perform the constant yet delicate balancing act required for ... robots that can balance like humans, researchers at Georgia Tech ...
Cached Biology News:Mixing large doses of both acetaminophen painkiller and caffeine may increase risk of liver damage 2Simulation reveals how body repairs balance after damage 2Simulation reveals how body repairs balance after damage 3